Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients [Phase 4]
Phase 4 study evaluating outcomes of early versus late G-CSF administration for primary prophylaxis in patients with non-Hodgkin's lymphoma …
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients [NA]
The clinical trial evaluating a decision support system for symptom self-management in Non-Hodgkin lymphoma patients has completed.
-
CLINICAL_TRIALS trial_result · 2025-01-24Clinical Trial Update: A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies [EARLY_Phase 1]
A Phase 1 study evaluating CTA30X cell injection in relapsed or refractory CD19-positive B-line hematological malignancies has completed.
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors [NA]
A Clinical Trial Update describes a novel CAR-T therapy expressing IL-15 for malignant hematological tumors, with recruitment ongoing and no…
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL [Phase 1]
Phase 1 study evaluating glofitamab in combination with either rituximab or obinutuzumab plus CHOP, or polatuzumab vedotin plus rituximab wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma [Phase 1]
Phase 1/2 study of AZD0466 in advanced Non-Hodgkin Lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating CART19 cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia and rela…
-
FDA label_change · 2025-01-03FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product…
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results w…
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis [Phase 2, Phase 3]
A multi-agent trial in pediatric and young adult patients explores preventing graft-versus-host disease after transplantation using post-tra…
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 1]
This Phase 1 trial assessed safety, tolerability, and maximum tolerated dose of BI 2536 in patients with recurrent advanced aggressive non-H…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 trial evaluating SIRPant-M in participants with relapsed or refractory Non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma [Phase 1]
Phase 1 trial testing EBV-specific cytotoxic T cells in relapsed EBV-positive lymphomas has completed, assessing safety and preliminary acti…
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS [Phase 1]
A Phase 1 study of FD-001 in recurrent/refractory acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndro…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: CAR-37 T Cells in Hematologic Malignancies [Phase 1]
Phase 1 trial update on CAR-37 T cells in hematologic malignancies shows the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL [Phase 1]
Phase 1 trial update evaluating safety, PK/PD, and clinical activity of KT-413 in adults with relapsed or refractory B-cell non-Hodgkin lymp…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial from the University of Sao Paulo evaluating a CD19-directed CAR-T cell therapy for relapsed/refractory acut…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.
This clinical trial update describes the development of prognostic models to predict response and toxicity to CAR-T cell therapy in patients…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
An extension study to evaluate the safety and efficacy of an anti-CD19 CAR-T product in patients with B-cell lymphoproliferative disorders, …
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma [Phase 3]
Phase 3 clinical trial update on managing pain and chemotherapy-related symptoms in people with multiple myeloma or lymphoma, with results p…
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the safety and efficacy of Mosunetuzumab in combination with Polatuzumab Vedotin in B-cell non-Ho…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) [Phase 1]
Phase 1 PANAMA trial evaluating a dual NAMPT/PAK4 inhibitor in patients with solid tumors or non-Hodgkin lymphoma was terminated, with resul…